This application for renewal of the UW/FHCRC CFAR includes the University of Washington, Fred Hutchinson Cancer Research Center, Seattle BioMed, and Seattle Children's Hospital, Foundation and Research Institute, and international partner institutions. Our CFAR has over 560 faculty, pre- and postdoctoral trainees, and research scientists. Matching financial support for our CFAR from partner institutions equals 35% of CFAR Direct Costs. The highly interdisciplinary CFAR membership represents 12 of the 16 UW Schools and Colleges and all five FHCRC Divisions. Annual external HIV/AIDS research, training, and service program funding to our four CFAR partners currently exceeds $362 million, including $160 million for 148 awards from six of seven CFAR co-sponsoring NIH institutes, OAR and the Fogarty Center. This warrants effective coordination and communication by the CFAR to optimize the return on investment. Strategic research priorities for the future are (1) Prevent New HIV Infections; (2) Improve HIV Disease Outcomes; (3) Expand Basic Science Discovery Research; and (4) Reduce HIV-Related Health Disparities. To achieve these aims, our goals are (1) Develop a New Generation of Young Innovative HIV/AIDS Researchers; and (2) Provide infrastructure, resources, and incentives for Sustainable Interdisciplinary Translational Science. Ten proposed Cores (three new or completely restructured) and three new Scientific Working Groups (SWGs) emphasize (1) Clinical, Epidemiology, Health Services, and Health Economics Research; (2) Socio- Behavioral and Prevention Research; and (3) Basic Discovery Research, including Retrovirology, Immunology, and Molecular Profiling/Computational Biology. Each Core has individual-level and population-level components, domestic and international components, and collaborations within and external to our CFAR. For the twenty-sixth year of the UW/FHCRC CFAR, we will continue to be innovative. A multi-stage Strategic planning process led to: (1) Merging current Clinical Research and Clinical Retrovirology Cores to improve efficiency and reduce costs; (2) Replacing the Computational Biology Core with a new Molecular Profiling and Computational Biology Core that synergizes FHCRC and UW strengths; (3) Creating an AIDS-Associated Infections and Malignancies Core from a successful SWG; and (4) Launching three new SWGs to build upon strong UW/FHCRC programs for research on Substance Abuse and HIV/STI; Implementation Science; and Curative Therapies for HIV. Cross-CFAR Cores (Administration, Developmental, Biometrics, and International) will support and interact with every Core. The CFAR will support and provide added value for future local, national and international HIV/AIDS research priorities.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027757-30
Application #
9285703
Study Section
Special Emphasis Panel (ZAI1-UKS-A (J1))
Program Officer
Namkung, Ann S
Project Start
1997-03-01
Project End
2018-05-31
Budget Start
2017-06-01
Budget End
2018-05-31
Support Year
30
Fiscal Year
2017
Total Cost
$3,704,354
Indirect Cost
$953,183
Name
University of Washington
Department
Public Health & Prev Medicine
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Fredericksen, Rob J; Mayer, Kenneth H; Gibbons, Laura E et al. (2018) Development and Content Validation of a Patient-Reported Sexual Risk Measure for Use in Primary Care. J Gen Intern Med 33:1661-1668
Wilson, Kate S; Wanje, George; Masese, Linnet et al. (2018) A Prospective Cohort Study of Fertility Desire, Unprotected Sex, and Detectable Viral Load in HIV-Positive Female Sex Workers in Mombasa, Kenya. J Acquir Immune Defic Syndr 78:276-282
Ikoma, Minako; Gantt, Soren; Casper, Corey et al. (2018) KSHV oral shedding and plasma viremia result in significant changes in the extracellular tumorigenic miRNA expression profile in individuals infected with the malaria parasite. PLoS One 13:e0192659
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Gómez, Laurén A; Crowell, Claudia S; Njuguna, Irene et al. (2018) Improved Neurodevelopment After Initiation of Antiretroviral Therapy in Human Immunodeficiency Virus-infected Children. Pediatr Infect Dis J 37:916-922
Thomson, Kerry A; Dhanireddy, Shireesha; Andrasik, Michele et al. (2018) Fertility desires and preferences for safer conception strategies among people receiving care for HIV at a publicly-funded clinic in Seattle, WA. AIDS Care 30:121-129
Lohman-Payne, Barbara; Gabriel, Benjamin; Park, Sangshin et al. (2018) HIV-exposed uninfected infants: elevated cord blood Interleukin 8 (IL-8) is significantly associated with maternal HIV infection and systemic IL-8 in a Kenyan cohort. Clin Transl Med 7:26
McGrath, Christine J; Singa, Benson; Langat, Agnes et al. (2018) Non-disclosure to male partners and incomplete PMTCT regimens associated with higher risk of mother-to-child HIV transmission: a national survey in Kenya. AIDS Care 30:765-773
Njuguna, Irene N; Wagner, Anjuli D; Omondi, Vincent O et al. (2018) Financial Incentives for Pediatric HIV Testing in Kenya. Pediatr Infect Dis J 37:1142-1144

Showing the most recent 10 out of 1275 publications